Work on new UK value-based pricing system to start next April
This article was originally published in Scrip
As part of sweeping reform planned for the National Health Service in England, the UK coalition government is to begin developing a new value-based pricing strategy for drugs next April, and plans to create a new Cancer Drugs Fund in the same month. The reforms also involve an overhaul of the way in which healthcare services are commissioned.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.